Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. Equipment
  3. cancer monotherapy
Show results for
Products
Services

Companies

News
Articles

Refine by
Locations

  • USA
  • Canada
  • Europe

  • Africa
  • Asia & Middle East
  • Australasia
  • Latin America
  • North America
Brands

  • immune-onc
  • ion genestudio
  • tonix

Cancer Monotherapy Equipment & Supplies

3 equipment items found

Ion GeneStudio - Model S5 - Next-Generation Sequencing (NGS) System

Ion GeneStudio - Model S5 - Next-Generation Sequencing (NGS) System

by:Thermo Fisher Scientific, LIMS & Laboratory Software   based inPhiladelphia, PENNSYLVANIA (USA)
Expand your research to cover 2M to 130M sequencing reads per run with this scalable platform. The Ion GeneStudio S5 systems are designed to enable a broad range of targeted next-generation sequencing (NGS) applications with speed and scalability. Five Ion S5 chips enable a sequencing throughput range of 2M to 130M reads per ...
CONTACT SUPPLIER

Tonix - Model TNX-1700 - Gastric and Colorectal Cancers Antibody

Tonix - Model TNX-1700 - Gastric and Colorectal Cancers Antibody

Manufactured by:Tonix Pharmaceuticals Holding Corp.   based inChatham, NEW JERSEY (USA)
TNX-1700 is a stabilized recombinant version of Trefoil Factor 2 (TFF2) and is being developed by Tonix as a biologic to treat gastric and colorectal cancers. TFF2 is a small, secreted protein, encoded by the TFF2 gene in humans that is expressed in gastrointestinal mucosa where it functions to protect and repair mucosa. TFF2 is also expressed at low levels in splenic immune cells and is now ...
CONTACT SUPPLIER

Immune-Onc - Model IO-108 - (Anti-LILRB2) Mechanisms of Action Program

Immune-Onc - Model IO-108 - (Anti-LILRB2) Mechanisms of Action Program

Manufactured by:Immune-Onc Therapeutics, Inc.   based inPalo Alto, CALIFORNIA (USA)
Immune-Onc is evaluating IO-108, an antagonist antibody targeting the myeloid checkpoint, LILRB2 (also known as ILT4). The U.S. FDA has cleared the IND application for IO-108 as a potential therapy for solid tumors. The company expects to begin clinical trials with IO-108 in the second half of ...
CONTACT SUPPLIER
  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT